Last update: Sept. 12, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Fully human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
Administration by subcutaneous injection once a month.
Since the last update we have not found any published data on its excretion in breast milk.
Its very high molecular weight makes transfer into breastmilk in significant quantities very unlikely
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
A 22-month-old infant whose mother was taking eremumab had no adverse effects; he had no infections or developmental problems (Henze 2019).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM